In vivo use of glutathione S-transferase activated nitric oxide donors
View Patent ↗The present invention provides for a method of simultaneously treating both cancer and the Multidrug Resistance Phenotype via inhibition of cellular thiols, such as Glutathione S-Transferase (GST). This enzyme is overproduced in leukemia and solid tumor cells and is one of the main pathways involved in the Multidrug Resistance phenotype. The treatment provides for the administration of a chemically inert pro-drug, designed to be a specific substrate for the GST enzyme that, once cleaved, liberates the bioactive toxin Nitric Oxide (NO) intracellularly at the site of a malignant growth. NO then acts to inhibit the growth of the malignant cells and to induce cellular differentiation and apoptosis therein, effectively treating an existing cancerous condition. Additionally, once NO is liberated from the pro-drug, the remaining structure acts to inhibit further GST activity, providing a treatment for the Multidrug Resistant phenotype.
1. A method for treating cancer in a human comprising
(a) identifying a human having cancer selected from the group consisting of prostate, renal, melanoma, colon, ovarian, lung, and central nervous system cancer; and
(b) administering to the human O 2 -(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K).
2. The method of claim 1 , wherein JS-K induces apoptosis of cancer cells in the human.
3. The method of claim 1 , wherein the administration of JS-K does not induce hypotension in the human.
4. The method of claim 1 , further comprising administration of a chemotherapeutic agent, radiation, or a combination thereof in conjunction with JS-K.
5. The method of claim 4 , wherein said chemotherapeutic agent is selected from the group consisting of 5-fluorouracil (5FU); etoposide (VP-16); actinomycin-D; mitomycin C; cisplatin (CDDP); doxorubicin; a podophyllotoxin; a DNA alkylating agent, or a camptothecin; and a combination of any of the above.
6. The method of claim 4 , wherein the radiation is X-rays, y-radiation, UV-radiation, microwaves, or electronic emissions.
7. The method of claim 4 , wherein JS-K and the chemotherapeutic agent and/or radiation are administered simultaneously or sequentially to the subject.
8. A method of killing a target cancer cell in a human comprising
(a) identifying a human having cancer selected from the group consisting of prostate, renal, melanoma, colon, ovarian, lung, and central nervous system-cancer;
and
(b) administering to the human O 2 -(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K).
9. The method of claim 8 , wherein JSK is administered with a DNA damaging agent.
10. The method of claim 8 , wherein JS-K induces apoptosis of cancer cells in the human.
11. The method of claim 8 , wherein the administration of JS-K does not induce hypotension in the human.
12. The method of claim 8 , further comprising administration of a chemotherapeutic agent, radiation, or a combination thereof in conjunction with JS-K.
13. The method of claim 12 , wherein said chemotherapeutic agent is selected from the group consisting of 5 -fluorouracil (5FU); etoposide (VP-16); actinomycin-D; mitomycin C; cisplatin (CDDP); doxorubicin; a podophyllotoxin; a DNA alkylating agent, or a camptothecin; and a combination of any of the above.
14. The method of claim 12 , wherein the radiation is X-rays, y-radiation, UV-radiation, microwaves, or electronic emissions.
15. The method of claim 12 , wherein JS-K and the chemotherapeutic agent and/or radiation are administered simultaneously or sequentially to the subject.
16. The method of claim 8 , wherein JSK is administered with a DNA damaging agent.